AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 156 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $292,619 | -22.6% | 11,823 | -11.5% | 0.18% | -20.5% |
| Q2 2023 | $378,214 | +65.8% | 13,355 | +34.5% | 0.22% | +77.8% |
| Q1 2023 | $228,138 | -16.7% | 9,932 | +1.8% | 0.13% | -11.9% |
| Q4 2022 | $273,864 | -29.8% | 9,753 | -29.3% | 0.14% | -8.3% |
| Q3 2022 | $390,000 | +29.1% | 13,803 | +1.5% | 0.16% | +39.3% |
| Q2 2022 | $302,000 | -10.1% | 13,602 | +17.9% | 0.11% | -25.3% |
| Q1 2022 | $336,000 | -11.3% | 11,541 | 0.0% | 0.15% | +4.9% |
| Q4 2021 | $379,000 | +4.7% | 11,541 | +47.0% | 0.14% | -10.1% |
| Q3 2021 | $362,000 | -23.3% | 7,849 | -8.4% | 0.16% | -18.0% |
| Q2 2021 | $472,000 | -50.1% | 8,573 | -53.2% | 0.19% | -51.5% |
| Q1 2021 | $946,000 | +22.5% | 18,328 | +2.8% | 0.40% | +25.0% |
| Q4 2020 | $772,000 | +77.9% | 17,822 | +43.7% | 0.32% | +40.4% |
| Q3 2020 | $434,000 | -28.5% | 12,398 | +9.2% | 0.23% | -20.6% |
| Q2 2020 | $607,000 | +35.8% | 11,354 | -9.9% | 0.29% | +56.0% |
| Q1 2020 | $447,000 | -31.4% | 12,600 | -7.8% | 0.18% | +72.0% |
| Q4 2019 | $652,000 | +39.6% | 13,663 | -5.2% | 0.11% | +13.8% |
| Q3 2019 | $467,000 | -44.4% | 14,418 | -14.4% | 0.09% | -46.9% |
| Q2 2019 | $840,000 | -14.4% | 16,847 | +15.9% | 0.18% | -91.5% |
| Q1 2019 | $981,000 | +84.4% | 14,540 | +26.1% | 2.09% | +2193.4% |
| Q4 2018 | $532,000 | -16.1% | 11,531 | +40.4% | 0.09% | +37.9% |
| Q3 2018 | $634,000 | -1.7% | 8,215 | +7.4% | 0.07% | -88.4% |
| Q2 2018 | $645,000 | -45.2% | 7,652 | -46.9% | 0.57% | -44.2% |
| Q1 2018 | $1,178,000 | +210.8% | 14,405 | +117.5% | 1.02% | +114.7% |
| Q4 2017 | $379,000 | -11.9% | 6,624 | +2.9% | 0.48% | +720.7% |
| Q3 2017 | $430,000 | +42.9% | 6,435 | +10.1% | 0.06% | +28.9% |
| Q2 2017 | $301,000 | -2.3% | 5,847 | +11.0% | 0.04% | -18.2% |
| Q1 2017 | $308,000 | +54.8% | 5,269 | +10.6% | 0.06% | -6.8% |
| Q4 2016 | $199,000 | -25.7% | 4,764 | -6.0% | 0.06% | -54.6% |
| Q3 2016 | $268,000 | +26.4% | 5,068 | 0.0% | 0.13% | -17.2% |
| Q2 2016 | $212,000 | +5.5% | 5,068 | +2.3% | 0.16% | -43.3% |
| Q1 2016 | $201,000 | – | 4,954 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |